

STUDY PROTOCOL

Pre-hospital early goal directed therapy for septic shock

Samu Save Sepsis - Study

Romain Jouffroy, Djillali Annane, Benoit Vivien, Papa Gueye

For the Samu Save Study group

Abstract

Background:

The major prognostic factor in the management of septic shock is the rapidity of the implementation of the effective treatments. To date, 2 early treatments are effective: hemodynamic optimization and antibiotherapy. In France, out of hospital emergencies are managed by the SAMU, corresponding to the emergency medical service. SAMU can dispatch a mobile intensive care unit (MICU) in order to manage the main organs deficiencies since the pre-hospital setting. The management of septic shock by the MICU in the pre-hospital setting is based on fluid volume expansion and oxygenation. Purpura fulminans is the sole situation where antibiotherapy is given without prior blood culture sampling.

The aim of this study is to provide clinical evidence that an “aggressive” strategy, including hemodynamic optimisation and antibiotherapy, instituted during the first 60 minutes in the pre-hospital setting reduce 30 day-mortality of patients with septic shock.

Methods/Design:

This trial is a multi-centric open label, cluster-randomized controlled study.

The study compares 2 strategies of care: one conventional and one “aggressive”.

A total of 550 patients, 275 per arm, with septic shock requiring MICU intervention in the pre-hospital setting will be included. 22 centres, 11 per arm, will participate to the study. Each centre will be allocated to one arm during the whole study (no cross-over).

The primary outcome is the mortality 30 days after hospital admission.

Intervention:

Patients who meet the inclusion criteria and none of the non-inclusion criteria will be included in the pre-hospital setting. In the conventional arm, cares are leaded to the physician discretion. Conversely, in the “aggressive “arm, during the first 60 minutes, the patient will receive antibiotherapy and hemodynamic optimisation (fluid volume expansion and norepinephrine if required) with a target of mean blood pressure of 65mmHg.

Discussion:

It is expected that the "aggressive" strategy in the first 60 minutes in the pre-hospital setting will allow a decrease of 28- and 90 days mortality, as well as the duration of mechanical ventilation and catecholamine's supports, in-ICU and in-hospital length of stay.

Trial registration: French ethics committee Paris Ile de France 2 on 2015/07/06 and the National Heart Agency (ID RCB number: 2014-A01030-47) approved the protocol on 2015/06/19.

Trial registration: Clinical Trial Number Register: NCT02473263

Keywords: Septic shock, pre-hospital, strategy, optimization, mortality.

Background

Sepsis is a major public health issue with an estimated incidence of 240 per 100 000 inhabitants in the United States (1). The increase of 90% in 10 years observed since 1990 is related to the aging of the population and a greater use of immunosuppressive therapies and invasive devices.

The epidemiology of sepsis, its impact on morbidity and its therapeutic management has been well studied in intensive care unit (ICU) (1 - 9). Most of the time sepsis comes from respiratory tract (50%), from digestive tract (25%) and rarely from urinary tract (5%). Sepsis related mortality remains high, around 30% at 28 days (10, 11) with a 40% overall mortality. The median length of stay is 10-15 days in ICU. For patients surviving to sepsis; the median in hospital length of stay often extends beyond one month. Therefore, sepsis costs are extremely high.

To date, the major prognostic element is the early recognition preceding effective treatment's initiation (12). Rivers et al. observed a significant decrease of mortality using an "aggressive" hemodynamic strategy aiming to early restore tissue perfusion (13).

In France, the management of out-of-hospital emergencies is based on the Service d'Aide Médicale d'Urgence (SAMU) corresponding to the emergency medical service. The SAMU hospital-based team is composed of switchboard operators and physicians. Over the phone, the physician determines the appropriate level of care to dispatch to the scene, based on patient's symptoms communicated by the patient itself, by a relative or a witness. For life-threatening emergencies, a mobile intensive care unit (MICU), composed of a driver, a nurse and an emergency physician, is dispatched to the scene. MICU is equipped with medical devices and drugs allowing initial management of main organs deficiency (neurological, respiratory and cardiovascular) (14). To date, the pre-hospital management of septic shock by MICU is still "conventional" based on fluid volume expansion and oxygenation. Antibiotherapy is only given in the presence of purpura

fulminans, without microbiological sampling.

The impact on mortality of a pre-hospital "aggressive" strategy based on hemodynamic optimization and antibiotic therapy, established during the first 60 minutes has never been evaluated.

The aim of this study is to provide clinical evidence that an "aggressive" strategy compared to "conventional" strategy allow a significant mortality decrease.

Methods/Design:

This trial is a multi-centric open label, cluster-randomized controlled study.

The study aims to compare 2 strategies allocated to the conventional arm or to the aggressive arm. A total of 550 patients, 275 per arm, with septic shock requiring MICU intervention in the pre-hospital setting will be included.

Twenty-two centres, 11 in each arm, will participate to the study.

Each centre will be allocated to one arm during the whole study (no cross-over) after randomisation prior the beginning of the study.

The primary outcome is the mortality 30 days after hospital admission.

French ethics committee Paris Ile de France 2 on 2015/07/06 and the National Heart Agency (ID RCB number: 2014-A01030-47) on 2015/06/19 approved the trial protocol.

This trial was registered with the Clinical Trial Number: NCT02473263.

Population

Patients with pre-hospital septic shock requiring MICU intervention will be recruited by the MICU physicians of the following hospitals: Fire Brigade of Paris, Paris – France; SAMU 75 - Necker enfants malades Hospital, Assistance Publique Hôpitaux de Paris, Paris – France; SAMU 75 - Pitié Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Paris – France; SAMU 75 - Hotel

Dieu Hospital, Assistance Publique Hôpitaux de Paris, Paris – France; SAMU 75 - Lariboisière Hospital, Assistance Publique Hôpitaux de Paris, Paris – France; SAMU 94 - Assistance Publique Hôpitaux de Paris, Créteil – France; SAMU 92 - Assistance Publique Hôpitaux de Paris, Garches – France; SAMU 93 - Assistance Publique Hôpitaux de Paris, Bobigny – France; SAMU 95 - Assistance Publique Hôpitaux de Paris, Pontoise – France; SAMU 78 - Versailles Hospital, Versailles – France; SAMU 77 - Melun Hospital, Melun – France; SAMU 76 - Rouen University Hospital, Rouen – France; SAMU 38 - Grenoble University Hospital, Grenoble – France; SAMU 69 - Lyon University Hospital, Lyon – France; SAMU 86 - Poitiers University Hospital, Poitiers – France; SAMU 29 - Brest University Hospital, Brest – France; SAMU 54 - Nancy University Hospital, Nancy – France; SAMU 974 – La Réunion University Hospital, La Réunion – France; SAMU 33 - Bordeaux University Hospital, Bordeaux – France; SAMU 80 - Amiens University Hospital, Amiens – France; SAMU 31 - Toulouse University Hospital, Toulouse – France; SAMU 45 - Orléans University Hospital, Orléans – France; SAMU 63 – Clermont Ferrand University Hospital, Clermont Ferrand – France; SAMU 85 – La Roche sur Yon University Hospital, La Roche sur Yon – France; SAMU 74 – Annecy Hospital, Annecy – France.

The previous 22 centres will be sampled before the beginning of the study, in 11 centres allocated to the conventional arm and 11 allocated to the aggressive arm.

The target sample size is 550 subjects: 275 in the conventional arm and 275 in the aggressive arm.

The purpose of the study will be explained to the patients or their relatives in order to obtain their oral consent prior to the inclusion. An additional information form will be provided to the participants' or their relatives.

Participants will be able to withdraw from the study at any time without consequence.

The trial will be executed from May 09th, 2016 to November 09th, 2018.

All recruit procedures will be recorded in a computer file.

Inclusion criteria

Patients with septic shock in the pre-hospital setting requiring MICU intervention and meeting the following criteria will be consecutively included:

1. Age > 18 years either sex
2. Severe sepsis according defined by an infectious disease and at least one the following:
 - * Low blood pressure prior to volume expansion
 - * Glasgow coma scale < 13
 - * Skin mottling score > 2
 - * Blood lactate level > 4 mmol.l⁻¹
3. Septic shock
4. Patient with health insurance
5. No objection to participate to the research expressed by the patient and/or relatives

Non-inclusion criteria

Patients meeting one or more of the following criteria will not be included:


1. Age < 18 years either sex
2. Pregnancy
3. Serious co morbid conditions with a not to be reanimated status known since pre-hospital setting
4. Patients with guardianship or curatorship
5. Purpura fulminans
6. Beta-lactamin allergy
7. Objection to participate to the research expressed by the patient and/or relatives

Interventions

All MICU of a SAMU will perform the same strategy, conventional or “aggressive”, during the whole study.

Thus, patients who meet the inclusion criteria and none of the exclusion criteria will benefit from blood culture sampling and thereafter will receive either conventional therapy (fluid volume expansion and oxygenation) either “aggressive” therapy since the pre-hospital setting by MICU during the first 60 minutes.

The “aggressive” therapy consists of antibiotherapy (ceftriaxone 2g for community infection or piperacillin-tazobactam 4g for nosocomiality defined by hospitalization within 3 previous-months) and hemodynamic optimisation based on fluid volume expansion (crystalloids 1000ml with a maximum of 35ml.kg^{-1} over 30 minutes) and norepinephrine if required with a target of mean blood pressure of 65mmHg. If mean blood pressure remains lower than 65mmHg with at least norepinephrine 1.5mg.h^{-1} , a corticosteroid (100mg hydrocortisone hemisuccinate) will be administered (Figure).



Randomization and blinding

To avoid the occurrence of the Hawthorne effect, the methodology of cluster has been chosen.

As the design of the study does not allow blinding, randomization will be performed prior to the beginning of the study.

Primary outcome measure

The primary outcome will be the 28-day mortality.

The mortality will be assessed by a phone-call on day 28 to wards or from medical report. If necessary, a phone call to the patient or relatives will be made.

Secondary outcome measures

Secondary outcomes criteria are:

- The hospital mortality will be evaluated on medical report after leaving the hospital.

If necessary, a phone call to the patient or relatives will be made.

- The 90-day mortality at day 90 will be evaluated by a phone call to wards or from medical reports after leaving the hospital. If necessary, a phone call to the patient or relatives will be made.

- The in-ICU and in-hospital length of stay as the duration of mechanical ventilation, extra-renal and catecholamine's supports will be evaluated from medical records of ICU and/or wards.

Safety

Physician will report any adverse events they experience, including all adverse events related to the study, especially serious adverse events related to treatments administered.

Sample size

We have performed sample size calculations based on ICU statistics relating an average 28-day mortality rate of 30% for septic shock (10, 11). The sample size was calculated, in order to reach 90% power for the demonstration of a 10% (absolute variation) decrease in the 28-day mortality

rate with a bilateral alpha risk of 5%. We hypothesized a 15% reduction in the mortality rate in case of an "aggressive" strategy compared to the conventional strategy.

The average inclusion of each centre is assumed to be near 25 patients over a two-year period.

We plan to enrol a total of 275 patients in each arm.

Data analysis

Descriptive statistics will be used to describe demographic and baseline characteristics of study participants.

The primary outcome will be analyzed using Generalized Estimated Equation (GEE) method taking into account the arm and the centre of allocation.

The accepted level of significance for all analyses will be $p < 0.05$.

Statisticians who are independent of the research team will conduct data analysis.

Discussion

To date, this study is the first open-label cluster randomized controlled clinical trial comparing the efficacy of the instauration of an "aggressive" strategy since the pre-hospital setting for patients with septic shock.

In the management of septic shock, the rapidity of treatments' instauration is recognized as a major prognostic element. In 2001, Rivers et al. observed the positive impact on mortality of the early hemodynamic optimization (13). In 2009, Arnold et al. observed a further mortality decrease achieved by that by introducing early antibiotherapy (15).

The principle of superiority of an early "aggressive" strategy based on the achievement of predetermined therapeutic objectives, against septic shock remains unclear. This superiority principle is supported by a meta-analysis performed in "high-risk" ICU patients, evaluating the impact of the early cardiac index and / or oxygen transport optimisation compared to a

conventional strategy (16). The positive impact of such a strategy consisting on rapid intervention procedure for the management of patients with shock has been observed in the emergency department as in wards (17).

The results of our study aims to provide a new evidence for the early instauration of an “aggressive” strategy for septic shock since pre-hospital setting.

Trial status

The trial is currently in the recruitment phase.

Funding

The « Samu Save Sepsis » trial is funded by the French Ministry of Health (Ministère des Solidarités et de la Santé) through the Inter Regional Clinical Research Program (Programme Hospitalier de Recherche Clinique Inter Régional).

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Romain Jouffroy conceived the study and drafted the manuscript.

Jean Paul Mira, Benoit Vivien and Pierre Carli helped to prepare the initial protocol.

All authors read and approved the final manuscript.

Acknowledgements

All members of EMS and ICU's team taking care of the patients included in the study.

Samu Save Study group

Benoît Vivien, Pierre Carli - SAMU - 75 Hôpital Necker Enfants Malades 149 rue de Sèvres 75015 Paris

Nace Lionel - SAMU 54- CHRU Nancy – Hôpital Central 29 Avenue du Maréchal de Lattre de Tassigny, 54000 Nancy

Ecollan Patrick SAMU - 75 Hôpital Pitié Salpêtrière 47-83 Boulevard de l'Hôpital, 75013 Paris

Adnet Frédéric - SAMU 93 - Hôpital Avicenne 125 rue de Stalingrad 93000 Bobigny

Heidet Mathieu - SAMU 94 - Hôpital Henri Mondor 51 avenue du maréchal De Lattre de Tassigny 94000 Créteil

Lefort Irène SAMU 85 - CH La Roche sur Yon – les Oudairies 85925 La Roche sur Yon Cedex 9

Pr Gueugniaud Pierre Yves - SAMU 69 - Hôpital Edouard Herriot 5 place d'Arsonval 69003 Lyon

Combes Xavier - SAMU 974 - CHU de la Réunion Hôpital Bellepierre 97405 Saint Denis Cedex

Mimoz Olivier - SAMU 86 - CHRU Poitiers 2 rue de la Miltérie 86000 Poitiers

Loeb Thomas - SAMU 92 - Hôpital Raymond Poincaré 104 boulevard Raymond Poincaré 92380 Garches

Gonzales Denis - SAMU 63 - CHRU Clermont Ferrand 58 rue Montalembert 63000 Clermont Ferrand

Papa Gueye - SAMU 75 - Hôpital Lariboisière 2 rue Ambroise Paré 75475 Paris Cedex 10

Richard Olivier - SAMU 78 - Centre Hospitalier André Mignot 177 rue de Versailles 78157 Le Chesnay Cedex

Boune Vincent - SAMU 31 - CHRU Toulouse place du Docteur Joseph Baylac 31000 Toulouse

Ricard Hibon Agnès - SAMU 95 - Centre Hospitalier René-Dubos 6 Avenue de l'Île de France - CS 90079 Pontoise - 95303 Cergy Pontoise

Cohen Rudy - SMUR Argenteuil - Centre Hospitalier Victor Dupouy 69 rue du Lt Col Prudhon
95100 Argenteuil

Tourtier Jean Pierre - Brigade de Sapeurs-Pompiers de Paris – service médical d’urgence 1 place
Jules Renard 75017 Paris

Dolveck François - SAMU 77 - CHG de Melun Rue Fréteau de Pény 77011 Melun

Debaty Guillaume - SAMU 38 - CHU de Grenoble CS 10217 - 38043 Grenoble Cedex 9

Moussa Soradjou - SAMU 33 – Hôpital Pellegrin CHU de Bordeaux. 33076 Bordeaux Cedex

Querellou Emgan - SAMU 29 - CHRU La Cavale Blanche BvD T.Prigent 29200 Brest

Ammirati Christine – SAMU 80 – CHRU Amiens Picardie 80054 Amiens Cedex 1

Benoit Jardel - SAMU 76 - CHU Hôpitaux de Rouen 1 rue de Germont 76031 Rouen Cedex

Narcisse Sophie - SAMU 45 - CH Orléans 1 rue porte Madeleine 45000 Orléans

Savary Dominique - SAMU 74 – Centre Hospitalier Annecy Genevois 1 avenue de l'hôpital Metz
- Tessy - BP 90074 74374 Pringy Cedex

Levrat Albrice - Centre Hospitalier Annecy Genevois 1 avenue de l'hôpital Metz - Tessy - BP
90074 74374 Pringy Cedex

Jouffroy Romain - Hôpital Necker – 149 rue de Sèvres 75015 Paris

Mira Jean Paul - Hôpital Cochin 27 rue du faubourg Saint Jacques 75014 Paris

Payen Didier - Hôpital Lariboisière 2 rue Ambroise Paré 75475 Paris Cedex 10

Mégarbane Bruno - Hôpital Lariboisière 2 rue Ambroise Paré 75475 Paris Cedex 10

Rabbat Antoine - Hôpital Cochin 27 rue du faubourg Saint Jacques 75014 Paris

Misset Benoit - Hôpital Saint Joseph 185 Rue Raymond Losserand, 75014 Paris

Fartoukh Muriel - Hôpital Tenon, 4 rue de la Chine 75970 Paris Cedex 20

Guidet Bertrand - Hôpital Saint Antoine 184 rue du faubourg Saint Antoine 75571 Paris

Timsit Jean François - Hôpital Bichat Claude Bernard 46 rue Henri Huchard 75877 Paris Cedex 18

Langeron Olivier - Hôpital Pitié Salpêtrière 47-83 boulevard de l'Hôpital, 75651 ParisCedex 13

Raux Mathieu - Hôpital Pitié Salpêtrière 47-83 boulevard de l'Hôpital, 75651 ParisCedex 13

Demoule Alexandre - Hôpital Pitié Salpêtrière 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13

Lescot Thomas - Hôpital Saint-Antoine 184, rue du Faubourg Saint-Antoine 75012 Paris

Jacob Laurent - Hôpital Saint-Louis 1, Avenue Claude Vellefeaux 75010 Paris

Mebazaa Alexandre - Hôpital Saint-Louis 1, Avenue Claude Vellefeaux 75010 Paris

Merat Stéphane - HIA Bégin 69 avenue de Paris 94160 Saint Mandé

Baillard Christophe - Hôpital Jean Verdier avenue du 14 juillet 93140 Bondy

Duranteau Jacques - Hôpital Bicêtre 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre

Cohen Yves - Hôpital Avicenne 125 rue de Stalingrad 93009 Bobigny

Ricard Jean Damien - Hôpital Louis Mourier 178 rue des Renouillers 92700, Colombes

Dhonneur Gilles - Hôpital Henri Mondor - 51 avenue du maréchal De Lattre de Tassigny 94000 Créteil

Bollaert Pierre Edouard - CHRU Nancy – Hôpital Central 29 Avenue du Maréchal de Lattre de Tassigny 54000 Nancy

Levy Bruno - CHRU Nancy – Hôpital Brabois 5 rue Morvan 54500 Vandoeuvre les Nancy

Vieillard Baron Antoine - Hôpital Ambroise Paré 9 avenue Charles de Gaulle 92100 Boulogne Billancourt

Cerf Charles - Hôpital Foch 40 rue Worth 92151 Suresnes

Trouiller Pierre - Hôpital Antoine Bécère 157 rue de la porte de Trivaux 92140 Clamart

Annane Djilali - Hôpital Raymond Poincaré, 104 boulevard Raymond Poincaré 92380 Garches

Constantin Jean Michel - CHU Estaing 1 place Lucie et Raymond Aubrac 63000 Clermont Ferrand

Souweine Bertrand - CHRU Gabriel Montpied Clermont Ferrand 58 rue Montalembert 63000 Clermont Ferrand

Guelon Dominique - CHU Gabriel Montpied Clermont Ferrand 58 rue Montalembert 63000 Clermont Ferrand

Mimoz Olivier - CHRU Poitiers 2 rue de la Miltérie 86000 Poitiers

Robert René - CHRU Poitiers 2 rue de la Miltérie 86000 Poitiers

Reignier Jean - CH La Roche sur Yon – les Oudairies 85925 La Roche sur Yon Cedex 9

Tonnelier Jean Marie – CHRU Brest Hôpital de la Cavale Blanche boulevard Tanguy Prigent 29609 Brest

Martinet Olivier - CHRU La Réunion – Site Nord

Boulain Thierry - CHR Orléans – Hôpital de La source 45067 Orléans

Bedos Jean Pierre - CH Versailles 177 Rue de Versailles 78150 Le Chesnay

Monchi Meran - CH Melun 6 rue Freteau de Peny 77000 Melun

Thuong Marie - CH René Dubos 6 avenue de l'Ile de France 95301 Pontoise

Boulet Eric - CH Pontoise 6 avenue de l'Ile-de-France 95303 Pontoise

Payen Jean François - CHRU Grenoble Hôpital Albert Michallon 38043 Grenoble Cedex

Schwebel Carole - CHRU Grenoble Hôpital Albert Michallon 38043 Grenoble Cedex

Durand Michel - CHRU Grenoble Hôpital Albert Michallon 38043 Grenoble Cedex

Lavagne Pierre - CHRU Grenoble Hôpital Albert Michallon 38043 Grenoble Cedex

Dureuil Bertrand - CHRU Rouen Hôpital Charles Nicolle 1 rue de Germont 76031 Rouen

Tamion Fabienne - CHRU Rouen Hôpital Charles Nicolle 1 rue de Germont 76031 Rouen

Cougot Pierre - CHRU Toulouse – Hôpital Rangueil 1 avenue du Professeur Jean Poulhès - TSA
50032 - 31059 Toulouse cedex 9

Riu Béatrice - CHRU Toulouse - Hôpital Purpan Place du Docteur Baylac - TSA 40031 - 31059
Toulouse cedex 9

Ouattara Alexandre - CHRU Bordeaux - Groupe Hospitalier Sud Avenue de Magellan 33604 -
PESSAC CEDEX

Hilbert Gilles - CHRU Bordeaux – Hôpital Pellegrin Place Amélie Raba-Léon, 33000 Bordeaux

Guisset Olivier - CHRU Bordeaux – Hôpital Saint André 1, rue Jean BURGNET 33075 Bordeaux

Labadie Philippe - HIA Robert Picque 351 route de Toulouse CS 80002 33882 Villenave d'Ornon
Cedex

Guerin Claude - CHRU Lyon – Hôpital Croix Rousse 93-103 grande rue de la croix rousse 69317
Lyon

Argaud Laurent - Centre Hospitalier Lyon – Hôpital Edouard Herriot Place d'Arsonval 69437
Lyon

Floccard Bernard - Centre Hospitalier Lyon – Hôpital Edouard Herriot Place d'Arsonval 69437
Lyon

Plantefeve Gaetan - Centre Hospitalier Victor Dupouy 69 rue du Lt Col Prudhon 95100 Argenteuil

Delbes François - GH Eaubonne Montmorency 14 rue de Saint Prix, 95600 EAUBONNE

Galbois Arnaud - Hôpital Privé Claude Galien 20 route de Boussy 91480 Quincy sous Sénart

References

1. Brun-Buisson C. The epidemiology of the systemic inflammatory response. *Intensive Care Med.* 2000;26 Suppl 1:S64-74.
2. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. *Intensive Care Med.* 2004 Apr;30(4):580-8.
3. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. *JAMA.* 1995 Sep 27;274(12):968-74.
4. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. *Am J Respir Crit Care Med.* 2003 Jul 15;168(2):165-72.
5. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. *Intensive Care Med.* 2002 Feb;28(2):108-21.
6. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med.* 2001 Jul;29(7):1303-10.
7. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. *Intensive Care Med.* 2004 Apr;30(4):589-96.
8. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med.* 2003 Apr 17;348(16):1546-54.

9. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. *Crit Care Med*. 2003 Sep;31(9):2332-8.
10. Nguyen HB, Van Ginkel C, Batech M, Banta J, Corbett SW. Comparison of Predisposition, Insult/Infection, Response, and Organ dysfunction, Acute Physiology And Chronic Health Evaluation II, and Mortality in Emergency Department Sepsis in patients meeting criteria for early goal-directed therapy and the severe sepsis resuscitation bundle. *Journal of critical care*. 2012 Aug;27(4):362-9.
11. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. *JAMA*. 2008 May 21;299(19):2294-303.
12. Pottecher T, Calvat S, Dupont H, Durand-Gasselin J, Gerbeaux P. Haemodynamic management of severe sepsis: recommendations of the French Intensive Care Societies (SFAR/SRLF) Consensus Conference, 13 October 2005, Paris, France. *Critical care (London, England)*. 2006;10(4):311.
13. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med*. 2001 Nov 8;345(19):1368-77.
14. Adnet F, Lapostolle F. International EMS systems: France. *Resuscitation* Oct 2004;63(1):7-9
15. Emergency Medicine Shock Research Network (EMShockNet) Investigators. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Arnold RC, Shapiro NI, Jones AE, Schorr C, Pope J. *Shock*. 2009 Jul;32(1):35-9.

16. Kern KB, Hilwig RW, Berg RA, Sanders AB, Ewy GA. Importance of continuous chest compressions during cardiopulmonary resuscitation: improved outcome during a simulated single lay-rescuer scenario. *Circulation*. 2002 Feb 5;105(5):645-9.
17. Sebat F, Johnson D, Musthafa AA, Watnik M, Moore S, Henry K, et al. A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients. *Chest*. 2005 May;127(5):1729-43.